SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis
Authors' conclusion
SGLT2 inhibitors have a distinct advantage over both placebo and other therapies at lowering EAT thickness, a result supported by direct comparisons and surface under the cumulative ranking curve analysis. Therefore, SGLT2 inhibitors should be prioritized as a treatment to reduce EAT in individuals with aberrant glucolipid levels, such as patients with T2DM and/or obesity.
Study context
- Population
- People with T2D, obesity, or T2D with obesity
- Participants
- 867 people16 trials
- Comparison
- SGLT2 inhibitors vs GLP-1 agonists vs exercise vs placebo vs conventional hypoglycaemic therapy
- Outcome
- Mean change in epicardial adipose tissue (EAT) thickness
Methodological detailsrandomized controlled trials and a small number of case-control studies, Searched PubMed, EMBASE, Cochrane Library, Web of Science before 31 January 2024
- Randomized controlled trials and a small number of case-control studies
- Searched PubMed, EMBASE, Cochrane Library, Web of Science before 31 January 2024
Pooled result
As reported in the abstract
EAT thickness change
SMD, cm (95% CI)
SGLT2 inhibitorsvs Placebo
−0.85(−1.39 to −0.31)
Exercisevs Placebo
−0.78(−1.37 to −0.18)
SGLT2 inhibitorsvs GLP-1 agonists
−0.74(−1.45 to −0.02)
SGLT2 inhibitorsvs Conventional hypoglycaemic therapy
−1.69(−2.38 to −0.99)
Further pooled results
| Outcome | MD (kg/m²) (95% CI) | |
|---|---|---|
| BMI changeSGLT2 inhibitorsvs Placebo | −0.90 (−1.14 to −0.66) | |
| −1.5−1−0.500.5Difference, kg/m² (linear scale) |
| Outcome | MD (%) (95% CI) | |
|---|---|---|
| HbA1c changeSGLT2 inhibitorsvs Placebo | −0.52 (−0.86 to −0.18) | |
| HbA1c changeGLP-1 agonistsvs Placebo | −0.48 (−0.93 to −0.03) | |
| −1−0.500.5Difference, % (linear scale) |
Total cholesterol, LDL-C, HDL-C changes
- Not statistically significant between interventions
Original publication
SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis. Diabetes Obes Metab. Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →